Search
Close this search box.
    • Small Molecules
      • Discovery
    • Biologics
    • Other Drug Modalities
    • SynVent Integrated Drug Discovery
      • SynVent Integrated Drug Discovery

        SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules. 

    • Industries
    • Emerging Biopharma
      • Emerging Biopharma

        Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.

    • Dedicated Centers
      • Dedicated Centers

        Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their  R&D  goals

    • Center for Advanced Protein Studies (CAPS)
      • Center for Advanced Protein Studies (CAPS)

        Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.

  • Careers
Search
Close this search box.

PK/PD Modeling and Simulations

Helping clients determine dosage levels for drug efficacy studies

Syngene offers pharmacokinetic/ pharmacodynamic (PK/PD) modeling and simulation expertise across a wide array of techniques and applications to helps clients select the appropriate dosage levels for efficacy studies. Using both science and art, we help clients choose an accurate model that provides insights into the pharmacokinetic parameters of a compound, and aid in the interpretation of dose-response and dose escalation studies during early clinical testing. Our models avoid bias, justify the goodness of fit, diagnostic, and graphical criteria, and help with accurate and precise prediction of pharmacokinetic parameters.

Our expert services provide a robust and effective way to characterize observed data and provide a strong foundation to simulate efficacy study designs. They include:

  • PK/PD/ efficacy correlations based on exposure or Cmax
  • PK modeling and simulations 
  • Scaling of preclinical PK to predict human PK using allometry approach
  • Prediction of first-in-human (FIH) and median efficacious doses (MED) 
  • Pharmacokinetic parameter evaluations using Phoenix WinNonlin

Your browser does not support this function.

To download, Please share your details

This Website uses Cookies

We use cookies to improve your experience on our site and show you information relevant to your requirements. To find out more, read our Privacy Policy and Cookies Policy.

To view or email, Please share your details view

To download, Please share your details